Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
PRX-PLUS has a unique product feature with its deep-impacting formula
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Subscribe To Our Newsletter & Stay Updated
